Research programme: Neurological disorder therapeutics - Foresee Pharmaceuticals
Alternative Names: FP-040Latest Information Update: 13 Nov 2023
At a glance
- Originator Foresee Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Aldehyde dehydrogenase 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 10 Oct 2023 Preclinical trials in Neurological disorders in USA (unspecified route) (Foresee Pharmaceuticals pipeline; October 2023)